CoChat

Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials

Open access
Monami, Matteo, Cremasco, Francesco, Lamanna, Caterina, Marchionni, Niccolò, Mannucci, Edoardo · 2011 · Diabetes/Metabolism Research and Reviews
Cited by 69

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aim: Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are used in the treatment of type 2 diabetes. Available sub‐group analysis of clinical trials does not allow a clear identification of predictors of therapeutic response to these drugs. The aim of this study is the assessment of predictors of response to DPP‐4 inhibitors. Materials and methods: A meta‐analysis was performed, exploring correlation between 24‐week effects on HbA 1c of maximal doses of DPP‐4 inhibitors, compared either with placebo or with other active drugs, matches to baseline characteristics of patients enrolled in 63 randomized clinical trials, either published or unpublished but disclosed on different websites were studied. Results: DPP‐4 inhibitors significantly reduce HbA 1c at 24 weeks [by 0.6 (0.5–0.7)%] when compared with placebo; no difference in HbA 1c was observed in comparisons with thiazolidinediones and α‐glucosidase inhibitors, whereas sulfonylureas and metformin produced a greater reduction of HbA 1c, at least in the short term. DPP‐4 inhibitors produced a smaller weight gain than thiazolidinediones, and showed a lower hypoglycaemia risk than sulfonylureas. The placebo‐subtracted effect of DPP‐4 inhibitors on HbA 1c was greater in older patients and in those with lower fasting plasma glucose at baseline. Similar results were obtained in comparisons with thiazolidinediones and metformin. Conclusions: Although drugs for type 2 diabetes are studied in heterogeneous samples of patients, their efficacy can be predicted by some clinical parameters. DPP‐4 inhibitors appear to be more effective in older patients with mild/moderate fasting hyperglycaemia. These data could be useful for a better definition of the profile of patients who are likely to benefit most from these drugs. Copyright © 2011 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.1184

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 69

Metadata

Authors
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., & Mannucci, E.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2011-05
Volume
27
Issue
4
Pages
362-372
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2019470196
Cited by
69
References
7
FWCI
6.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials. https://app.cochat.ai/papers/10.1002/dmrr.1184
The paper
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., & Mannucci, E. (2011). Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.1184

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.